## **Clare Loane**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2049828/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants. Science Translational Medicine, 2010, 2, 38ra46.	12.4	272
2	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	7.6	219
3	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	4.4	213
4	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	8.2	202
5	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain, 2013, 136, 400-411.	7.6	172
6	InÂvivo visualization of age-related differences in the locus coeruleus. Neurobiology of Aging, 2019, 74, 101-111.	3.1	117
7	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. Science Translational Medicine, 2012, 4, 128ra41.	12.4	107
8	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology, 2013, 80, 1850-1855.	1.1	95
9	Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Scientific World Journal, The, 2011, 11, 1726-1734.	2.1	76
10	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	3.9	49
11	Positron emission tomography neuroimaging in Parkinson's disease. American Journal of Translational Research (discontinued), 2011, 3, 323-41.	0.0	48
12	<sup>11</sup> Câ€₽E2I and <sup>18</sup> Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	3.9	45
13	Association between precuneus volume and autobiographical memory impairment in posterior cortical atrophy: Beyond the visual syndrome. NeuroImage: Clinical, 2018, 18, 822-834.	2.7	43
14	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	3.1	42
15	Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiology of Disease, 2011, 43, 609-615.	4.4	40
16	Ambient particulate matter and its potential neurological consequences. Reviews in the Neurosciences, 2013, 24, 323-35.	2.9	36
17	Hippocampal network abnormalities explain amnesia after VGKCC-Ab related autoimmune limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 965-974.	1.9	32
18	Network-wide abnormalities explain memory variability in hippocampal amnesia. ELife, 2019, 8, .	6.0	30

CLARE LOANE

#	Article	IF	CITATIONS
19	Lateral parietal contributions to memory impairment in posterior cortical atrophy. Neurolmage: Clinical, 2018, 20, 252-259.	2.7	25
20	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.	3.9	18
21	Pathologic tearfulness after limbic encephalitis. Neurology, 2020, 94, e1320-e1335.	1.1	12
22	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.	2.2	9
23	Functional Specialization of the Medial Temporal Lobes in Human Recognition Memory: Dissociating Effects of Hippocampal versus Parahippocampal Damage. Cerebral Cortex, 2022, 32, 1637-1652.	2.9	6
24	Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. Parkinsonism and Related Disorders, 2021, 87, 61-69.	2.2	2